An independent 12-week clinical trial has produced statistically significant evidence that Altrient Glutathione measurably reduces skin redness and improves hyperpigmentation across the entire face. Conducted by PCR Corp — a specialist consumer product clinical research organisation — the study enrolled 33 healthy adults with self-assessed uneven skin tone and pigmentation, of whom 31 completed the full study duration. No adverse reactions were reported.

Using validated chromameter technology (CIE L*a*b* colour space), independent expert clinical grading, and subject self-perception questionnaires, the data demonstrate clear, consistent improvement across all assessment methods and all facial measurement sites.

Statistically significant at p<0.01 across all measurements. 100% of completing subjects showed improvement at every facial site assessed.

The study was designed as a single-centre, home-use trial, running from December 2023 to March 2024 at PCR Corp's Manchester facility. It was conducted in full compliance with the Declaration of Helsinki and ICH E6(R2) Good Clinical Practice guidelines.

Participants

Thirty-three adults aged 20 to 60 (mean age 38.45) were enrolled, all presenting with self-assessed uneven skin tone and pigmentation. The cohort was deliberately diverse:

Subjects were asked to continue their existing skincare routines unchanged, avoid any new supplements or skincare products, and refrain from all professional facial treatments — including peels, laser, IPL, and microdermabrasion — for the full 12 weeks.

Test Article

The test article was Altrient Glutathione / Lypo-Spheric Glutathione (AGSH0423/BAR), delivered as a 5.4ml liposomal sachet. Each serving contained 450mg of Setria L-Glutathione (reduced form) encapsulated within 1,000mg of phospholipids, of which 500mg was phosphatidylcholine. Subjects consumed two sachets daily — one morning, one early afternoon — preferably on an empty stomach.

The liposomal delivery system is integral to the product's efficacy. Standard oral glutathione is substantially degraded in the gastrointestinal tract before reaching systemic circulation; phospholipid encapsulation protects the active compound and enables direct cellular uptake, supporting meaningful increases in plasma glutathione levels at the doses used.

How the Skin Was Assessed

Measurements were taken at baseline (Day 1) and again at Week 12, across four facial sites: right cheek, left cheek, forehead, and chin. Three complementary assessment methods were used:

• Chromameter CR300® (CIE L*a*b*): Objective, instrument-based skin colour measurement. The a* value quantifies redness (lower = less red); the b* value quantifies yellow-orange pigmentation tone (lower = less pigmented). Both are standard, validated metrics in dermatological and cosmetic clinical research.
• Expert Clinical Visual Grading: An independent trained evaluator assessed hyperpigmentation severity and skin tone evenness under standardised conditions at both timepoints, using a validated PCR clinical grading scale.
• Self-Perception Questionnaire (SPQ): Subjects completed a 20-question questionnaire at Week 12, rating their agreement with statements about their skin using a five-point Likert scale.

The a* value is the standard instrument-based measure of skin redness. A reduction in a* represents a direct, objective decrease in cutaneous redness and vascular-related discolouration — one of the most visible contributors to uneven skin tone. The results across all four facial measurement sites at Week 12 were statistically significant (p<0.01), with 100% of subjects showing measurable improvement at every site.

All results: p<0.01  |  100% of subjects improved  |  n=31

The consistency of this result across every facial site — and across every single participant — is particularly notable. Reductions approaching 80% in measured redness, achieved without exception across a diverse group including Fitzpatrick Types II through VI, demonstrate both the potency of the liposomal glutathione formulation and the reliability of the effect.

The b* value captures yellow-to-orange pigmentation tone in the skin. Elevated b* readings are associated with more pronounced discolouration, uneven pigmentation, and visible dark spots. Reductions in b* indicate an objective, measurable improvement in skin pigmentation uniformity. Again, results across all four sites were statistically significant (p<0.01), with 100% subject improvement at every location.

All results: p<0.01  |  100% of subjects improved  |  n=31

A consistent reduction of approximately 57% in chromameter-measured pigmentation was achieved across the full face in 12 weeks. The symmetry of results across left and right cheeks, forehead, and chin — all within a narrow range — reflects a systemic, whole-face effect consistent with an orally administered supplement acting through the bloodstream rather than a topically applied product.

The objective instrument data are corroborated in full by independent expert clinical visual grading. The same trained evaluator assessed all subjects under controlled conditions at both baseline and Week 12 — ensuring consistent, unbiased scoring.

Hyperpigmentation & Skin Discolouration

Overall hyperpigmentation and mottled skin discolouration, assessed on a validated 0–9 scale, improved from a mean score of 5.00 at baseline to 2.37 at Week 12 — a mean reduction of 2.63 points, representing a 52.58% improvement (p<0.01). Every completing subject showed a clinically visible improvement.

Skin Tone Evenness

Skin tone evenness — scored on the same 0–9 scale, where lower scores represent more even tone — improved from a mean of 7.45 at baseline to 3.13 at Week 12 — a mean reduction of 4.32 points and a 58.01% improvement (p<0.01). Once again, 100% of subjects demonstrated visible improvement as assessed by the clinical expert.

After 12 weeks of use, all 31 completing subjects completed a detailed questionnaire about their experience with the product. The results reflect the objective data strikingly well. All 20 claims exceeded the 70% top-box agreement threshold required under Clearcast guidelines for substantiation.

Skin Tone & Pigmentation

• 80.65%  agreed their skin looks more even
• 80.65%  agreed their skin tone looks improved
• 74.19%  agreed it corrects uneven-looking skin tone
• 74.19%  agreed it fades the look of dark spots
• 77.42%  agreed the look of discolouration is lighter

Radiance & Overall Skin Appearance

• 96.77%  agreed their skin is visibly brighter
• 93.55%  agreed their skin looks more radiant and luminous
• 93.55%  agreed their skin looks healthier
• 93.55%  agreed their skin looks less dull
• 90.32%  agreed their skin looks younger with a youthful glow
• 90.32%  agreed their skin is visibly improved overall
• 74.19%  agreed their complexion is clearer

Product Experience

• 87.10%  said they would recommend this product
• 77.42%  said it is a great addition to their skincare routine
• 74.19%  said they love how it makes their skin look and feel
• 70.97%  agreed it visibly improves signs of ageing

The results of this independent 12-week clinical trial are clear and consistent: Altrient Glutathione produces statistically significant, measurable improvements in both skin redness and hyperpigmentation, confirmed across multiple validated assessment methods and a diverse participant population.

Chromameter measurements showed reductions in skin redness of approximately 79% and in pigmentation-related discolouration of approximately 57% — both statistically significant at p<0.01 and achieved by 100% of completing participants. Independent expert clinical grading confirmed visible improvements in hyperpigmentation (52.58%) and skin tone evenness (58.01%). Subjects' own perceptions aligned closely with the objective data, with all 20 self-perception claims substantiated above the Clearcast threshold.

The mechanism is well-established in the scientific literature. Glutathione inhibits tyrosinase — the key enzyme in melanin production — and shifts melanin synthesis towards lighter phaeomelanin. It simultaneously neutralises the oxidative stress that drives post-inflammatory hyperpigmentation and vascular redness. The liposomal delivery system in Altrient Glutathione ensures these effects are achievable at clinically meaningful levels, overcoming the bioavailability limitations of conventional oral glutathione supplements.

Altrient Glutathione is independently, clinically validated to reduce skin redness and improve hyperpigmentation — with statistically significant results across a diverse population of 31 subjects over 12 weeks, and a 100% response rate.

This report summarises PCR Corp independent clinical study ABUSUP1M, conducted at PCR Corp Manchester between December 2023 and March 2024. The study was sponsored by Abundance and Health Ltd. and Livon Labs, and conducted under the Declaration of Helsinki (2013) and ICH E6(R2) Good Clinical Practice guidelines. An independent quality assurance audit of the report was completed by PCR Corp's QA team. Full study data are available on request. No adverse reactions were reported across the study. Raw data retained for a minimum of 15 years from study completion.